Specify a stock or a cryptocurrency in the search bar to get a summary
Prostatype Genomics AB
PROGENProstatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients, as well as provides decision support for patients and doctors when making a treatment decision. Prostatype Genomics AB (publ) was incorporated in 2007 and is based in Solna, Sweden. Address: Gustaf III:s Boulevard 34, Solna, Sweden, 169 73
Analytics
WallStreet Target Price
5.9 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PROGEN
Dividend Analytics PROGEN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PROGEN
Stock Valuation PROGEN
Financials PROGEN
Results | 2019 | Dynamics |